9,462 reports of this reaction
1.7% of all HYDROXYCHLOROQUINE SULFATE reports
#11 most reported adverse reaction
CONTRAINDICATED PRODUCT ADMINISTERED is the #11 most commonly reported adverse reaction for HYDROXYCHLOROQUINE SULFATE, manufactured by Advanz Pharma (US) Corp.. There are 9,462 FDA adverse event reports linking HYDROXYCHLOROQUINE SULFATE to CONTRAINDICATED PRODUCT ADMINISTERED. This represents approximately 1.7% of all 558,480 adverse event reports for this drug.
Patients taking HYDROXYCHLOROQUINE SULFATE who experience contraindicated product administered should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONTRAINDICATED PRODUCT ADMINISTERED is a less commonly reported adverse event for HYDROXYCHLOROQUINE SULFATE, but still significant enough to appear in the safety profile.
In addition to contraindicated product administered, the following adverse reactions have been reported for HYDROXYCHLOROQUINE SULFATE:
The following drugs have also been linked to contraindicated product administered in FDA adverse event reports:
CONTRAINDICATED PRODUCT ADMINISTERED has been reported as an adverse event in 9,462 FDA reports for HYDROXYCHLOROQUINE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONTRAINDICATED PRODUCT ADMINISTERED accounts for approximately 1.7% of all adverse event reports for HYDROXYCHLOROQUINE SULFATE, making it a notable side effect.
If you experience contraindicated product administered while taking HYDROXYCHLOROQUINE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.